Relations of serum visfatin and resistin levels with endometrial cancer and factors associated with its prognosis

Basit Öğe Kaydı
dc.contributor.authorİlhan, Tolgay Tuyan
dc.contributor.authorKebapcılar, Ayşe Gül
dc.contributor.authorYılmaz, Setenay Arzu
dc.contributor.authorİlhan, Türkan
dc.contributor.authorKerimoğlu, Özlem Seçilmiş
dc.contributor.authorPekin, Aybike Tazegül
dc.contributor.authorAkyürek, Fikret
dc.contributor.authorÜnlü, Ali
dc.contributor.authorÇelik, Çetin
dc.date.accessioned2020-03-26T19:08:30Z
dc.date.available2020-03-26T19:08:30Z
dc.date.issued2015
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractBackground: The aims of this study were compare the serum visfatin and resistin levels between endometrial cancer (EC) patients and controls and evaluate their power to predict prognosis. Materials and Methods: This prospective study was conducted between March 2013 to June 2014 on the Gynecologic Oncology Department of the University of Selcuk, Konya, Turkey. A total of 42 EC patients and 42 controls were included and assessed for differences in serum visfatin and resistin levels, along with prognostic factors. Results: Endometrial cancer patients had significantly higher visfatin levels than control s (p: 0.011), associated with deep myometrial invasion (p: 0.019). In contrast the serum level of resistin did not significantly differ between EC patients and controls (p: 0.362). However, high resistin level in EC patients was associated with increase lymph node metastasis (p: 0.009). On logistic regression analysis, we found that serum visfatin elevation was associated with risk of myometrial invasion (OR: 1,091; 95%CI: 1.021- 1.166; p: 0.010) and serum resistin with risk of lymph node metastasis (OR: 1.018; 95%CI: 1.000- 1.035; p: 0.046). For myometrial invasion prediction, a serum visfatin level greater than 26.8 ng/mL demonstrated a sensitivity and specificity of 66.6 % and 96.4%, respectively. For lymph node metastasis prediction, the best cut-off for serum resistin level was 599ng/mL. A serum resistin level greater than this demonstrated a sensitivity and specificity of 87.5% and 77.1%, respectively. Conclusions: Our data suggest that serum visfatin is elevated in patients with EC and serum visfatin and resistin levels could be used to predict the risk of advance stage lesions.en_US
dc.identifier.doi10.7314/APJCP.2015.16.11.4503en_US
dc.identifier.endpage4508en_US
dc.identifier.issn1513-7368en_US
dc.identifier.issue11en_US
dc.identifier.pmid26107194en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage4503en_US
dc.identifier.urihttps://dx.doi.org/10.7314/APJCP.2015.16.11.4503
dc.identifier.urihttps://hdl.handle.net/20.500.12395/32855
dc.identifier.volume16en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAsian Pacific Organization for Cancer Preventionen_US
dc.relation.ispartofAsian Pacific Journal of Cancer Preventionen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectAdipocytokineen_US
dc.subjectEndometrial canceren_US
dc.subjectResistinen_US
dc.subjectVisfatinen_US
dc.titleRelations of serum visfatin and resistin levels with endometrial cancer and factors associated with its prognosisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu